![FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN](https://media.cnn.com/api/v1/images/stellar/prod/230109124641-moderna-bivalent-vaccine.jpg?c=original)
FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN
![ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine | Australian Government Department of Health and Aged Care ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/2022-11/atagi-recommendations-on-use-of-the-pfizer-bivalent-original-omicron-ba-1-covid-19-vaccine.png)
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine | Australian Government Department of Health and Aged Care
![BioNTech SE on X: "We completed, together with @Pfizer, the submission to the @US_FDA requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for BioNTech SE on X: "We completed, together with @Pfizer, the submission to the @US_FDA requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for](https://pbs.twimg.com/media/FdkzD95XEAAmQq3.jpg:large)
BioNTech SE on X: "We completed, together with @Pfizer, the submission to the @US_FDA requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for
BioNTech SE on LinkedIn: Pfizer and BioNTech Report New Data on Omicron BA .4/BA.5-Adapted Bivalent…
![Omicron BA.4/BA.5-adapted bivalent vaccine generates higher antibody response - Hospital Pharmacy EuropeHospital Pharmacy Europe Omicron BA.4/BA.5-adapted bivalent vaccine generates higher antibody response - Hospital Pharmacy EuropeHospital Pharmacy Europe](https://hospitalpharmacyeurope.com/wp-content/uploads/2022/10/Omicron-BA.4-BA.5-adapted-bivalent-vaccine-generates-higher-antibody-response.jpg)
Omicron BA.4/BA.5-adapted bivalent vaccine generates higher antibody response - Hospital Pharmacy EuropeHospital Pharmacy Europe
![Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster | Nature Medicine Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-02162-x/MediaObjects/41591_2022_2162_Fig1_HTML.png)
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster | Nature Medicine
![Covid: Aifa approva il vaccino bivalente Comirnaty sviluppato contro Omicron 4-5 | Sanità24 - Il Sole 24 Ore Covid: Aifa approva il vaccino bivalente Comirnaty sviluppato contro Omicron 4-5 | Sanità24 - Il Sole 24 Ore](https://www.sanita24.ilsole24ore.com/images2014/Editrice/ILSOLE24ORE/QUOTIDIANO_SANITA/2022/09/15/Quotidiano%20Sanita/ImmaginiWeb/Clipboard-0016.png)
Covid: Aifa approva il vaccino bivalente Comirnaty sviluppato contro Omicron 4-5 | Sanità24 - Il Sole 24 Ore
![News - CHMP Recommends Additional Authorisation Modification of Comirnaty (BioNTech/Pfizer) As a Bivalent Vaccine Adapted to Omicron BA.4/BA.5 for Booster Vaccinations - Paul-Ehrlich-Institut News - CHMP Recommends Additional Authorisation Modification of Comirnaty (BioNTech/Pfizer) As a Bivalent Vaccine Adapted to Omicron BA.4/BA.5 for Booster Vaccinations - Paul-Ehrlich-Institut](https://www.pei.de/SharedDocs/Bilder/EN/newsroom-en/hp-news-pm/omicron-ba5-chmp.jpg?__blob=thumbnail&v=6)
News - CHMP Recommends Additional Authorisation Modification of Comirnaty (BioNTech/Pfizer) As a Bivalent Vaccine Adapted to Omicron BA.4/BA.5 for Booster Vaccinations - Paul-Ehrlich-Institut
![Pfizer asks FDA to authorize Covid booster shots that target omicron BA.5 for people ages 12 and older Pfizer asks FDA to authorize Covid booster shots that target omicron BA.5 for people ages 12 and older](https://image.cnbcfm.com/api/v1/image/106810418-1607785676560-AP20347485617712.jpg?v=1607785740&w=929&h=523&vtcrop=y)
Pfizer asks FDA to authorize Covid booster shots that target omicron BA.5 for people ages 12 and older
![News - CHMP Recommends Authorisation of Comirnaty Variant (BioNTech/Pfizer) Adapted to Omicron BA.4/BA.5 As Booster Vaccination for Children Aged 5 to 11 Years - Paul-Ehrlich-Institut News - CHMP Recommends Authorisation of Comirnaty Variant (BioNTech/Pfizer) Adapted to Omicron BA.4/BA.5 As Booster Vaccination for Children Aged 5 to 11 Years - Paul-Ehrlich-Institut](https://www.pei.de/SharedDocs/Bilder/EN/newsroom-en/hp-news-pm/comirnaty-booster-opinion-adolescents.jpg?__blob=thumbnail&v=4)